01 June 2018
GoPath Laboratories, IntegraGen’s licensing partner in the U.S., has announced that it will launch a propriety new test, miR-31now™ during the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2018 in Chicago. The miR-31now test is the first positive theranostic test for patients with (…) »
25 May 2018
IntegraGen will be in attendance at 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago from June 1st to June 5th. The Annual ASCO Meeting brings together more than 32,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new (…) »
17 March 2018
IntegraGen is pleased to announce that a comprehensive summary of the results of validation studies associated with the company’s proprietary miR-31-3p expression test has been published online in Biomarker Insights following peer-review.
The paper entitled “Technical validation of a reverse-transcription quantitative polymerase chain reaction in vitro (…) »
23 October 2017
IntegraGen has been nominated for a 2017 MedStartup award, an initiative between The Galien Foundation and Business France to encourage and reward international partnerships between French and North American innovators in the Life Sciences Industry. IntegraGen was selected as a nominee by an (…) »
02 June 2017
The BIO International Convention (BIO) attracts 16,000 biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. The convention brings together a wide spectrum of life science and application areas including genomics, drug discovery, (…) »
04 January 2017
IntegraGen will be in attendance at 35th Annual JP Morgan Healthcare Conference being held in San Francisco on January 9-12, 2017. The J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry which brings together global industry leaders, emerging fast-growth companies, innovative (…) »
04 September 2016
Results from a new analysis of the predictive miR 31-3p biomarker for metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 clinical trial will be featured as an oral presentation during a proffered session at the upcoming 2016 European Society of Medical Oncology (ESMO) Congress. Professor Pierre Laurent-Puig, (…) »
10 June 2016
19 May 2016
The results from an analysis of miR 31-3p expression for metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 trial will be presented at ASCO 2016 in Chicago during a poster discussion session being held from 1:15 p.m. to 2:30 p.m. on Saturday, June 4, 2016 (Hall D). (…) »
17 March 2016
